Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
The Lancet. Oncology|September 18, 2015
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 studyMarinus H J van Oers, Kazimierz Kuliczkowski, Lukáš Smolej, et al.Blood|February 22, 2007
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphomaYoun H Kim, Madeleine Duvic, Erik Obitz, et al.Leukemia & Lymphoma|July 9, 2016
Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapyRoxanne C Jewell, Thomas J Kipps, Jan Dürig, et al.Leukemia & Lymphoma|January 20, 2016
Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemiaAnders Österborg, Miklós Udvardy, Andrey Zaritskey, et al.Leukemia & Lymphoma|November 11, 2016
Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLLTadeusz Robak, Krzysztof Warzocha, K Govind Babu, et al.The Lancet. Haematology|December 5, 2016
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 studyRichard R Furman, Herbert A Eradat, Christine G DiRienzo, et al.British Journal of Haematology|September 17, 2013
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphomaBertrand Coiffier, John Radford, André Bosly, et al.Leukemia & Lymphoma|October 13, 2016
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trialTadeusz Robak, Krzysztof Warzocha, K Govind Babu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD StudyGustaaf W van Imhoff, Andrew McMillan, Matthew J Matasar, et al.Blood|May 23, 2013
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphomaMatthew J Matasar, Myron S Czuczman, Maria Alma Rodriguez, et al.Pageof 3